Sunitinib is a cancer medication used to treat renal cell carcinoma, pancreatic cancer, kidney cancer, and imatinib-resistant gastrointestinal stromal tumor. It is marketed in 12.5mg, 25mg, and 50mg sunitinib oral capsule form. In most markets, the only sunitinib drug available is Sutent, produced by manufacturer CPPI CV (a subsidiary of Pfizer). First granted marketing authorization from the FDA in 2006, Sutent is now approved in and distributed to over 110 countries and has been used for the treatment of over 350,000 patients worldwide. Since its release, it has become a popular pharmaceutical choice across all of its indications, in spite of pressure for substitute medications, such as pazopanib (marketed as Votrient by supplier Novartis), and axitinib (marketed as Inlyta by supplier Pfizer). Supplier Pfizer maintains market exclusivity for sunitinib in many markets, with patents set to expire in the U.S. and Europe only 2021. In some countries, however, manufacturer and supplier Teva pharma have managed to obtain approval to market a generic version of sunitinib. Due to high costs associated with the manufacturing process, sunitinib can be regarded and has reportedly been criticized for being, a very expensive medication.

Sunitinib inhibits a variety of RTKs, some of which are connected to the development of tumours, pathologic angiogenesis, and the spread of cancer through metastasis. Platelet-derived growth factor receptors, vascular endothelial growth factor receptors, stem cell factor receptor, Fms-like tyrosine kinase-3 colony arousing factor receptor type 1, and the glial cell-line sourced neurotrophic factor receptor were all found to be targets of sunitinib's inhibitory activity against a variety of kinases. Biochemical and cellular experiments have shown that sunitinib inhibits the activity of several RTKs, and cell proliferation assays have shown that sunitinib inhibits function. In molecular and physiological studies, the main metabolite shows comparable potency to sunitinib.

The EU retail prices of the drug are approximately 1050-1100 EUR for 28 12.5mg sunitinib capsules, and 4200-4250 EUR for the same amount of 50mg capsules. That being said, generic sunitinib can cost up to two times less. Sunitinib is available for sale from various Sunitinib vendors at multiple costs. The price of Sunitinib is higher than that of such substitutes, owing largely to the more costly manufacturing process needed to produce it. Also, the costs of Sunitinib vary depending on manufacturer and supplier pricing, whether it is a generic or trade name formulation, concentration of the active ingredient in the formulation. It is available or sale at every medical store. Sunitinib suppliers, on the whole, are in favor of patient aid initiatives.

Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified Sunitinib manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform. Buyers are advised to buy from PipelinePharma. Making use of Pipelinepharma's worldwide B2B online marketplace for medications and other pharmaceuticals is the ideal approach to locate and acquire access to Sunitinib manufacturers and suppliers. Finding reliable suppliers and manufacturers of particular medications like Sunitinib can typically be a time-consuming challenge, but with Pipelinepharma's straightforward search engine and network of tested partners, the entire process becomes much simpler. Utilizing our built-in search engine, all you have to do to begin going is start looking for potential Sunitinib suppliers or manufacturers. You may also use filters to narrow down your search results and look for Sunitinib from particular nations.

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Sunitinib offerings can be narrowed down with filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for this substance manufacturer and Sunitinib suppliers that you are looking for. These also enable you to check the dossier status of this medicine and the GMP approvals of the different variants of Sunitinib. Also, each manufacturer or supplier product description contains essential information about this substance, including clinical data, stability zones, and countries in which Sunitinib is already registered. Manufacturers also have special delivery terms.

Suppose you are a pharmaceutical licensing company or a distributor. In that case, you can enter into deals or negotiations over these medicine offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps ensure that you conclude the pharmaceutical deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and order process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the Sunitinib suppliers. This way, the marketplace allows you as a distributor to skip the process of making a list of product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than Good Manufacturing Practice approvals that this medicine manufacturers list has, we qualify their companies before they are boarded on the platform. This allows us to screen Sunitinib manufacturers for the quality of the pharmaceutical products' dossiers and protect against the risk of possible malpractices.